AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...
AbbVie leads a Zacks Analyst Blog roundup highlighting strong pharma execution, AI-driven chip gains and an aviation rebound.
MarketBeat on MSN
AbbVie call options spike 2,599%: Tracking the big bet
Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large ...
Zacks Investment Research on MSN
ANIP vs. TEVA: Which drug stock is the better buy right now?
Both ANI Pharmaceuticals ANIP and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on generic and ...
Going into 2026, biotech company Ladder Bio is embracing a new identity.
The top Manufacturing stories this week include J&J and AbbVie's deals with the US, NVIDIA's collaboration with Eli Lilly and ...
Verywell Health on MSN
5 IBS-C Triggers That Aren’t Food
C, but there are several other situations that can lead to symptoms. Learn how stress, sleep, hormones, medications, and routine changes can trigger IBS-C symptoms and what strategies may help manage ...
The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab and ocrelizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback